Congratulations Houston!
Congratulations to Houston for passing his proposal defense!
Welcome back Ge!
We are very excited that Ge Shi has moved to Texas to rejoin our group as a research associate!
Phase IIb 180-day results
180 days post single treatment results: 45% complete response, 22% partial response, 11% no response, 22% yet undetermined (n=11). Taken from the Theralase 2020Q4 newsletter.
Welcome Elam!
The McFarland Group is happy to welcome our newest post doc Dr. Elamparuthi Ramasamy to the lab!
FDA grants Fast Track Designation for the trial
The U.S. Food and Drug Administration has granted Fast Track Designation to the Phase II Non-Muscle Invasive Bladder Cancer clinical study, opening the possibility of an Accelerated Approval and Priority Review. More details can be found at the Theralase press release.